ClinicalTrials.gg
Not yet recruitingNCT07939100DUALMAMOUpdated Nov 16, 2026

Study on Integrating the Systematic Detection of Breast Arterial Calcifications (BAC) in Routine Mammograms Within a Population-based Breast Cancer Screening Programme to Improve Cardiovascular Prevention in Women.

An interventional study of blood test and Lifestyle Evaluation in Cardio Vascular Disease and Risk Factor, Cardiovascular, sponsored by Hospital del Mar Research Institute (IMIM). Not yet recruiting. Open to female participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hospital del Mar Research Institute (IMIM) · Not applicable, Interventional, and Prevention

How we know

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Study summary

Heart disease is the leading cause of death in women, yet it often goes undetected until it's too late. This project uses a simple clue found during routine breast cancer screenings-breast arterial calcification (BAC)-to spot early signs of heart risk in women aged 50 to 70. Those identified with BAC will be invited to take part in a personalized prevention program. This includes support to adopt healthier habits-like being more active, eating better, sleeping well, and managing stress-and regular checks of key health measures such as blood pressure and cholesterol. The study will compare two levels of care: a nurse-led program and a more intensive, app-supported version.

By turning mammograms into a dual-purpose tool for breast and heart health, this project empowers women with early action to reduce risk and improve long-term well-being.

Read the detailed description

Background and rationale Cardiovascular disease (CVD) is a leading cause of death in women, and cardiovascular risk is frequently underrecognized in this population. Breast arterial calcification (BAC), a form of medial vascular calcification visible on mammography, has been associated with increased cardiovascular risk. Because mammography is already performed in population-based breast cancer screening, BAC offers an opportunity to identify women who may benefit from cardiovascular prevention without additional imaging or radiation exposure. Artificial intelligence (AI) algorithms enable automated, scalable BAC detection within screening workflows.

Study design DUALMAMO combines two components: (1) AI-based detection of BAC in screening mammograms from Hostpital del Mar breast cancer screening program, and (2) a randomized controlled trial among eligible BAC-positive women, comparing a digital multicomponent lifestyle intervention with standard primary care advice. The study assesses whether this strategy improves cardiovascular risk factor control and, over longer follow-up, reduces major adverse cardiovascular events. Outcomes are detailed in the Outcome Measures section.

Procedures Women are eligible once their screening result is known. BAC-positive women are identified by the AI algorithm and invited by letter to participate through the study app/web platform. After informed consent, participants attend a baseline in-person visit (questionnaires, blood test, and clinical measurements) and are randomized through the app. A second in-person visit takes place at 6 months, with the blood test repeated if no recent result is available. Clinical events are followed up to 36 months through.

Implementation The trial also evaluates recruitment, retention, adherence, and cost-effectiveness to inform the potential integration of BAC-based cardiovascular risk identification into routine breast cancer screening.

02

Conditions studied

  • Cardio Vascular Disease
  • Risk Factor, Cardiovascular

Keywords

  • breast arterial calcification
  • mammography
  • cardiovascular prevention
  • cardiovascular risk
  • preventive intervention
03

In context

Lead sponsor

Hospital del Mar Research Institute (IMIM) is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women participating in the population-based mammography screening program in the Hospital del Mar.
  • Presence of breast arterial calcification (BAC+) on the screening mammogram, as detected by the AI algorithm, ang confirmed by the Radiologists
  • Access to an internet-connected device and ability to use the study app/web platform.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Breast cancer diagnosis or recall for additional testing following the screening mammogram.
  • History of stroke, myocardial infarction, or angina pectoris.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Diagnostic Test: blood test · Behavioral: Lifestyle Evaluation · Behavioral: Digital Cardiovascular Health Education and Personalized Physical Activity Program

  • Active comparator
    Control Group

    Diagnostic Test: blood test · Behavioral: Lifestyle Evaluation · Behavioral: Usual Care Cardiovascular Counseling

Interventions

  • Diagnostic testblood test

    A blood test to determine the following: -Colesterol total (mg/dL) * Colesterol LDL (mg/dL) * Colesterol HDL (mg/dL) * Triglicéridos (mg/dL) * Glucosa en ayunas (mg/dL) * Hemoglobina glicosilada (HbA1c, %) * Lp(a)

  • BehavioralLifestyle Evaluation

    Cardiovascular risk factors questionnaire Patient Health Questionnaire-9 (PHQ-9) EuroQol 5-Dimension (EQ-5D) Chrononutrition Profile - Questionnaire (CP-Q) International Physical Activity Questionnaire (IPAQ)

  • BehavioralDigital Cardiovascular Health Education and Personalized Physical Activity Program

    Participants receive 6 months of access to a digital platform with structured educational modules on cardiovascular risk factors (sleep, diet, cholesterol, glucose, weight, physical activity, blood pressure, smoking and environmental factors), together with a personalized physical activity program. Participants also receive their baseline laboratory results review and the same information leaflet on breast arterial calcification (BAC) provided to the usual care arm. Allocation is by random assignment through the study application.

  • BehavioralUsual Care Cardiovascular Counseling

    Participants receive personalized cardiovascular health advice reflecting routine primary care practice, together with written information on BAC and its cardiovascular significance.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving cardiovascular risk control targets

    LDL cholesterol \<100 mg/dL, blood pressure \<140/90 mmHg, and/or ≥20% reduction in cardiovascular risk

    Time frame: 6 months

Secondary outcomes

  1. Change in depressive symptoms

    PHQ-9

    Time frame: 6 months

  2. Change in health-related quality of life

    EuroQol-5 (EQ-5D)

    Time frame: 6 months

  3. Change in physical activity

    IPAQ

    Time frame: 6 months

  4. Change in crononutrition profile

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939100
Lead sponsor
Hospital del Mar Research Institute (IMIM)
Responsible party
Helena Tizón Marcos (PhD, MD, Hospital del Mar Research Institute (IMIM)) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion